23andMe’s first patent on gene variant for Parkinson’s disease raises hopes, hackles

andMe
Image: U.S. Patent and Trademark Office

The recent news of 23andMe’s first patent shows how patents on natural genes continue despite the complex legal situation faced by other companies, and despite an explicitly stated ethos of openness and “democratization.” 23andMe has patented methods for screening the naturally occurring variants of the human genome they found to be associated with risk for Parkinson’s disease. The announcement on the company’s blog, The Spittoon, clarifies what they hope the patent will and won’t do.

Additional Resources:

Comments are closed.

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend